RESUMO
In this study, we used the nanoparticle delivery system to reduce the side effect of conventional cancer treatment- radiation therapy and chemotherapy. We used rice husk silicon source mesoporous silica nanoparticle doped in Eu3+ and Gd3+ as the carrier in the delivery system and to enable fluorescence and MRI dual-imaging functions for follow-up therapy. In addition, we choose a popular seaweed extract-fucoidan was extracted from the same brown algae-Sargassum aquifolium collected from Taiwan-Pingtung-Kenting-Chuanfan Rock. In this research, we used acid hydrolysis to prepared two different molecular weight fucoidan, the small molecular fucoidan (Fus) as drug, and the molecular weight approximately 1 kDa fucoidan (Ful) as the nanoparticle gatekeeper, and as targeting molecule for overexpressed P-selectin on the surface of the metastatic tumors. The results of the cell cytotoxicity experiment showed that HCT116 cancer cells have a survival rate of approximately 58.12% when treated with 200 µg/mL fucoidan. Dual-imaging rice husk mesoporous silica nanoparticles (rMSN-EuGd) were modified with 1 kDa fucoidan (Ful) as the gatekeeper and target, and the small molecule fucoidan (Fus) was loaded into nanoparticles (Ful-Fus@rMSN-EuGd) at a concentration of 200 µg/mL. The HCT116 cancer cells had a survival rate of approximately 55.56%. The cell cytotoxicity experiment results show that Ful-Fus@rMSN-EuGd can improve the anticancer effect of fucoidan, and the nanoparticle drug delivery system using fucoidan as a drug, target, and gatekeeper was successfully synthesized.
Assuntos
Nanopartículas , Neoplasias , Oryza , Sargassum , Humanos , Nanopartículas/uso terapêutico , Neoplasias/patologia , Polissacarídeos/farmacologia , Dióxido de SilícioRESUMO
IL-19 belongs to the IL-10 family, which includes IL-10, IL-19, IL-20, IL-22, melanoma differentiation-associated gene-7 (IL-24), and AK155 (IL-26). IL-10 has been shown to inhibit allergen-induced airway hyperreactivity and inflammation. To determine whether IL-19 was also associated with asthma, we used ELISA to analyze the serum level of IL-19 in patients with asthma and found that their serum IL-19 levels were twice those of healthy controls. Patients with a high level of IL-19 also had high levels of IL-4 and IL-13. In a dust mite-induced murine model of asthma, we found that IL-19 level in asthmatic BALB/cJ mice was also twice that of healthy control mice. IL-19 transcript was also induced in the lungs of asthmatic mice. Electroporation i.m. of the IL-19 gene into healthy mice up-regulated IL-4 and IL-5, but not IL-13. However, IL-19 up-regulated IL-13 in asthmatic mice. In vitro, IL-19 induced IL-4, IL-5, IL-10, and IL-13 production by activated T cells. Activation of T cells was required for induction of IL-13 because IL-19 did not induce IL-13 production on nonstimulated T cells. Taken together, these results demonstrated that IL-19 up-regulates Th2 cytokines on activated T cells and might play an important role in the pathogenesis of asthma.
Assuntos
Asma/imunologia , Citocinas/biossíntese , Interleucina-10/biossíntese , Interleucina-10/fisiologia , Células Th2/imunologia , Células Th2/metabolismo , Regulação para Cima/imunologia , Adulto , Animais , Asma/metabolismo , Linfócitos T CD4-Positivos/imunologia , Linfócitos T CD4-Positivos/metabolismo , Criança , Pré-Escolar , Modelos Animais de Doenças , Feminino , Humanos , Imunoglobulina E/biossíntese , Interleucina-10/sangue , Interleucina-10/genética , Interleucina-13/biossíntese , Interleucina-13/sangue , Interleucina-13/genética , Interleucina-4/biossíntese , Interleucina-4/sangue , Interleucina-5/biossíntese , Interleucinas , Células Jurkat , Ativação Linfocitária/imunologia , Camundongos , Linfócitos T/imunologia , Linfócitos T/metabolismo , Transcrição GênicaRESUMO
BACKGROUND: The efficacy of hepatitis B immunoglobulin (HBIG) in infants of hepatitis B e antigen (HBeAg)-negative hepatitis B surface antigen (HBsAg) carrier mothers in Taiwan is not clear. OBJECTIVE: To describe the responses of infants born to HBeAg-negative carrier mothers receiving HBIG combined with hepatitis B vaccine. METHODS: Term babies born to HBeAg-negative carrier mothers were assigned based on chart number to 1 of the 2 treatment groups. Group A infants (n = 94) received 0.5 ml (145 IU) of HBIG within 24 h of birth and 3 subsequent doses of recombinant hepatitis B virus (HBV) vaccine at 3 to 5 days, 1 month and 6 months of age. Group B infants (n = 122) received 3 doses of vaccines only. Infants (n = 19) born to HBeAg-positive carrier mothers were treated like those in Group A and are referred to as Group C. Sera obtained from infants at 2 and 7 months of age were tested for hepatitis B virus (HBV) markers. RESULTS: There were 2 (1%; one in Group A and one in Group B) subclinical breakthrough hepatitis B infections among studied infants. One (5%) child of Group C had asymptomatic HBV infection at the age of 7 months and became a chronic carrier. The rate of protective anti-hepatitis B surface antibody (anti-HBs) titers achieved (>10 mIU/ml) by 2 months of age was significantly higher in Group A than that in Group B (98% vs. 57%, P < 0.001). However, it was not different by 7 months of age. Infants (Group A) immunized with HBIG and vaccine had a significantly higher geometric mean titer (GMT, milli-International Units/ml) of anti-HBs than those (Group B) with vaccines only at 2 months of age (P < 0.001). Conversely at 7 months of age, the GMT of anti-HBs was significantly higher in infants who received vaccine only (P = 0.001). CONCLUSIONS: A protective level of antibodies was achieved earlier in those infants receiving both passive and active immunizations. However, infants receiving active immunizations alone achieved a higher GMT at 7 months of age. There was no clear benefit of passive-active vs.active immunization alone for chronic HBV infection in infants of HBsAg-positive, HBeAg-negative mothers.
Assuntos
Portador Sadio/imunologia , Vacinas contra Hepatite B/administração & dosagem , Hepatite B/tratamento farmacológico , Imunoglobulinas/administração & dosagem , Complicações Infecciosas na Gravidez/imunologia , Estudos de Casos e Controles , Relação Dose-Resposta a Droga , Esquema de Medicação , Feminino , Seguimentos , Hepatite B/congênito , Hepatite B/imunologia , Antígenos E da Hepatite B/análise , Antígenos E da Hepatite B/imunologia , Humanos , Recém-Nascido , Masculino , Gravidez , Complicações Infecciosas na Gravidez/prevenção & controle , Resultado da Gravidez , Probabilidade , Estudos Prospectivos , Medição de Risco , Testes Sorológicos , Estatísticas não Paramétricas , Taiwan , Resultado do TratamentoAssuntos
Anormalidades Múltiplas/diagnóstico , Doenças Fetais/diagnóstico , Diagnóstico Pré-Natal , Trigêmeos , Anormalidades Múltiplas/diagnóstico por imagem , Anormalidades Múltiplas/patologia , Adulto , Cesárea , Diagnóstico Diferencial , Feminino , Fertilização in vitro , Doenças Fetais/diagnóstico por imagem , Doenças Fetais/patologia , Humanos , Recém-Nascido , Masculino , Gravidez , UltrassonografiaRESUMO
We report a case of a solitary liver abscess in a 5-week-old female. She was full term, and there were no predisposing events or immune deficiencies. The only sign of her disease was a gradually distended abdomen. A prior episode of fever with possible occult bacteremia was implicated in the development of her abscess. The abdominal sonography and magnetic resonance image (MRI) did not provide any definite preoperative diagnostic information. Surgical resection of the abscess and a short course of antibiotic therapy cured the disease. This patient was still well following 2 years of check-ups by sonography. The possibility of a pyogenic liver abscess should be considered in the differential diagnosis of neonatal hepatic mass. That is, even if there is not a definite diagnostic focus on finding an infection.